Drugs / GB-5267
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07489287 | Jul 2026 → Jan 2028 expected | refractory malignant neoplasm | Roswell Park Cancer Institute | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GB-5267 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07489287 ↗ |
| Modality | Cell therapy | “an IL-18 Armored CAR T Cell Product Targeting MUC16” NCT07489287 ↗ |
| Route | Intravenous | “IV infusion” NCT07489287 ↗ |
| Target | MUC16 | “an IL-18 Armored CAR T Cell Product Targeting MUC16” NCT07489287 ↗ |